Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. - De Leeuw,I.; Vague,P.; Selam,JL.; Skeie,S.; Lang,H.; Draeger,E.; Elte,JWF. (Diabetes Obes Metab, 2005)